Your browser is no longer supported. Please, upgrade your browser.
Settings
LOXO Loxo Oncology, Inc. daily Stock Chart
LOXO [NASD]
Loxo Oncology, Inc.
Index- P/E- EPS (ttm)-3.65 Insider Own7.20% Shs Outstand30.47M Perf Week5.81%
Market Cap5.08B Forward P/E- EPS next Y-4.20 Insider Trans-43.55% Shs Float29.26M Perf Month3.80%
Income-109.20M PEG- EPS next Q-0.84 Inst Own99.80% Short Float7.41% Perf Quarter-4.63%
Sales102.30M P/S49.67 EPS this Y-53.30% Inst Trans-4.57% Short Ratio6.38 Perf Half Y46.40%
Book/sh13.00 P/B12.83 EPS next Y-138.60% ROA-16.40% Target Price211.43 Perf Year95.03%
Cash/sh22.02 P/C7.57 EPS next 5Y- ROE-28.20% 52W Range71.45 - 208.95 Perf YTD98.09%
Dividend- P/FCF22.12 EPS past 5Y- ROI-40.30% 52W High-20.30% Beta2.25
Dividend %- Quick Ratio3.60 Sales past 5Y- Gross Margin- 52W Low133.07% ATR5.22
Employees96 Current Ratio3.60 Sales Q/Q- Oper. Margin- RSI (14)54.91 Volatility2.86% 3.41%
OptionableYes Debt/Eq0.00 EPS Q/Q66.00% Profit Margin- Rel Volume2.00 Prev Close166.75
ShortableYes LT Debt/Eq0.00 EarningsAug 09 BMO Payout- Avg Volume339.63K Price166.53
Recom1.70 SMA201.72% SMA500.86% SMA20021.45% Volume151,318 Change-0.13%
Sep-25-18Initiated Leerink Partners Outperform
Sep-17-18Initiated Goldman Neutral $165
Aug-10-18Reiterated Stifel Buy $225 → $217
Jun-04-18Reiterated Stifel Buy $190 → $225
May-17-18Reiterated Stifel Buy $145 → $190
Apr-16-18Upgrade Morgan Stanley Equal-Weight → Overweight
Mar-21-18Downgrade Morgan Stanley Overweight → Equal-Weight
Feb-22-18Initiated Oppenheimer Outperform $132
Nov-28-17Initiated William Blair Outperform
Aug-29-17Downgrade JMP Securities Mkt Outperform → Mkt Perform
Jun-05-17Upgrade Citigroup Neutral → Buy
Jun-05-17Reiterated Stifel Buy $52 → $71
Apr-03-17Initiated Morgan Stanley Overweight $59
Mar-10-17Downgrade Citigroup Buy → Neutral
Feb-08-17Initiated Jefferies Buy $50
Mar-16-16Reiterated Stifel Buy $37 → $36
Jan-15-16Initiated Citigroup Buy $32
Nov-11-15Reiterated Stifel Buy $26 → $37
Sep-02-14Initiated Stifel Buy $20
Sep-02-14Initiated Oppenheimer Outperform $20
Sep-25-18 04:20PM  Loxo Oncology Announces LOXO-292 Durability Update in Patients with RET Fusion-Positive Non-Small Cell Lung Cancer from LIBRETTO-001 at the IASLC 19th World Conference on Lung Cancer GlobeNewswire
Sep-18-18 06:45AM  Loxo Oncology Announces Accepted Abstracts at the 88th Annual Meeting of the American Thyroid Association GlobeNewswire
Sep-13-18 08:45AM  3 Lung Cancer Stocks That Could End September on a High Note Motley Fool
Sep-06-18 04:14PM  5 Health Care Stocks in Gurus' Portfolios GuruFocus.com
Sep-05-18 09:55AM  Bayer open for drug licensing deals, cutting debt remains priority Reuters
06:45AM  Loxo Oncology Announces Receipt of Breakthrough Therapy Designation from U.S. Food and Drug Administration for LOXO-292 GlobeNewswire
Sep-02-18 09:33AM  3 Biotech Stocks That Could Soar in September Motley Fool
Aug-29-18 06:45AM  Loxo Oncology to Present at Upcoming Investor Conferences GlobeNewswire
Aug-28-18 04:00AM  Edited Transcript of LOXO earnings conference call or presentation 9-Aug-18 12:00pm GMT Thomson Reuters StreetEvents
Aug-27-18 02:30AM  Loxo Oncology Announces Submission of European Marketing Authorization Application for Larotrectinib GlobeNewswire
Aug-10-18 04:30PM  Loxo Oncology Announces Accepted Abstracts at the IASLC 19th World Conference on Lung Cancer GlobeNewswire
Aug-09-18 08:10AM  Loxo Oncology (LOXO) Reports Q2 Loss, Tops Revenue Estimates Zacks -7.18%
07:04AM  Loxo: 2Q Earnings Snapshot Associated Press
06:45AM  Loxo Oncology Reports Second Quarter 2018 Financial Results GlobeNewswire
06:00AM  Loxo Oncology Inc to Host Earnings Call ACCESSWIRE
Aug-08-18 09:18AM  Drug/Biotech Stock Q2 Earnings on Aug 9: PRGO, BDSI & More Zacks
Aug-02-18 06:45AM  Loxo Oncology to Announce Second Quarter 2018 Financial Results GlobeNewswire
Jul-17-18 07:35AM  Breakfast Technical Briefing on Mirati Therapeutics and Three Other Additional Biotech Stocks ACCESSWIRE
Jul-11-18 08:10AM  Today's Research Reports on Stocks to Watch: Loxo Oncology and OnoCyte ACCESSWIRE
Jun-20-18 12:00AM  Finding Cancer Patients Is Pharma Industry's Unlikely Challenge Bloomberg
Jun-11-18 08:20AM  Today's Research Reports on Trending Tickers: Loxo Oncology and Geron Corporation ACCESSWIRE
Jun-08-18 08:47AM  Here's Why Loxo Oncology Stock Gained 40.8% in May Motley Fool
06:04AM  3 Cancer Stocks That Could Soar in the Second Half of 2018 Motley Fool
Jun-07-18 08:10AM  New Research Coverage Highlights Durect, Credit Suisse Group, Obsidian Energy, TransCanada, Golden Star Resources, and Loxo Oncology Consolidated Revenues, Company Growth, and Expectations for 2018 GlobeNewswire
Jun-04-18 04:23PM  Why #ASCO18 Caused Blueprint Medicines Shares To Tumble Up to 16% Today Motley Fool
04:21PM  Here Are Winners And Losers From 2018's Biggest Cancer Drug Meeting Investor's Business Daily
03:32PM  Merck emerges as key winner at ASCO conference CNBC Videos
01:18PM  5 Biotech Stocks Moving On ASCO Presentations Benzinga
12:45PM  Loxo CEO on genetically targeted cancer drugs CNBC Videos
09:40AM  Merck Leads Dow As Stocks Move Higher: These 2 China Names Advance Investor's Business Daily
09:36AM  Loxo shares surge 8% on early-stage cancer drug trial MarketWatch
09:00AM  Options Traders Expect Huge Moves in Loxo Oncology (LOXO) Stock Zacks
08:05AM  Dow Jones Futures Lead Gains: These 6 Stocks Are In Focus Today Investor's Business Daily
07:00AM  Five key takeaways from ASCO, the world's largest cancer research conference CNBC
Jun-03-18 02:10PM  #ASCO18: A Weekend of Surprises Motley Fool
11:25AM  These 4 Hot Nasdaq Stocks Blasted To New All-Time Highs Last Week Forbes
Jun-02-18 10:17AM  Loxo Scores A Success With Second Targeted Cancer Drug Forbes
09:00AM  Loxo Promised Improved Data For Experimental Cancer Drug And Delivers Investor's Business Daily
09:00AM  Loxo Oncology Announces Positive Interim Clinical Data from LOXO-292 Dose Escalation Trial in RET-Altered Cancers Presented at the American Society of Clinical Oncology Annual Meeting GlobeNewswire
08:52AM  New Data Helps Loxo's Cause in Developing Targeted Cancer Drugs Bloomberg
08:00AM  Loxo Oncology posts improved results for newest cancer drug Reuters
Jun-01-18 04:40PM  Conquering cancer in the Windy City CNBC Videos +5.28%
May-31-18 06:01PM  The Big Thing to Watch at ASCO 2018 Motley Fool
11:53AM  Loxo Oncology's Candidates Are 'Impressive,' Piper Jaffray Says In Bullish Initiation Benzinga
May-29-18 07:34AM  Loxo-Bayer cancer drug gets priority review from FDA Reuters
06:45AM  FDA Accepts Larotrectinib New Drug Application and Grants Priority Review PR Newswire
06:45AM  FDA Accepts Larotrectinib New Drug Application and Grants Priority Review GlobeNewswire
May-19-18 09:32AM  Does a Blue Ribbon Make This Biotech Stock a Buy Now? Motley Fool
May-18-18 04:51PM  Winners and Losers From the Biggest Cancer Meeting of the Year (So Far) Motley Fool
10:16AM  This Tiny Cancer Drug Upstart Just Got Even More Interesting Motley Fool
08:10AM  Todays Research Reports on Stocks to Watch: Loxo Oncology and Jounce Therapeutics ACCESSWIRE
May-17-18 01:52PM  Here's Why Loxo Oncology Rose as Much as 23.3% Today Motley Fool +20.09%
10:39AM  Loxo Oncology shares surge 21% on preview of cancer drug trial data MarketWatch
09:31AM  Benzinga Pro's 5 Stocks To Watch Today Benzinga
09:19AM  UPDATE 1-Loxo Oncology's targeted RET drug shows promise in early trial Reuters
07:15AM  Dow Jones Futures Today: These 2 Tech Stocks Near Buys Move On Earnings; This Biotech Soars Investor's Business Daily
May-16-18 05:38PM  After-hours buzz: CSCO, JACK & more CNBC
05:18PM  Loxo Oncology's targeted RET drug shows promise in early trial Reuters
05:00PM  Loxo Oncology Announces Details of LOXO-292 Clinical Data Presentations at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting GlobeNewswire
May-15-18 03:52PM  Edited Transcript of LOXO earnings conference call or presentation 8-May-18 12:00pm GMT Thomson Reuters StreetEvents
May-08-18 06:45AM  Loxo Oncology Reports First Quarter 2018 Financial Results GlobeNewswire
May-07-18 04:30PM  Loxo Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
May-01-18 06:45AM  Loxo Oncology to Announce First Quarter 2018 Financial Results GlobeNewswire
Apr-24-18 08:27AM  How Blueprint Medicines Got The Blues Forbes
Apr-17-18 11:41AM  Loxo Oncology (LOXO) Shares March Higher, Can It Continue? Zacks
08:10AM  Todays Research Reports on Stocks to Watch: Clovis Oncology and Loxo Oncology ACCESSWIRE
Apr-16-18 09:52AM  Morgan Stanley Upgrades Loxo On The Potential Of A Targeted Cancer Therapy Benzinga +8.50%
Apr-12-18 07:45AM  Investor Expectations to Drive Momentum within Loxo Oncology, Kinross Gold, Marlin Business Services, lululemon athletica inc, LG Display Co., and QIWI Discovering Underlying Factors of Influence GlobeNewswire
Apr-10-18 08:06AM  Loxo, Illumina to partner for diagnostic tool targeting cancer Reuters +8.21%
07:44AM  Loxo and Illumina in partnership over diagnostic for cancer drug Reuters
06:45AM  Loxo Oncology and Illumina to Partner on Developing Next-Generation Sequencing-Based Pan-Cancer Companion Diagnostics GlobeNewswire
06:45AM  Illumina and Loxo Oncology to Partner on Developing Next-Generation Sequencing-Based Pan-Cancer Companion Diagnostics Business Wire
Apr-05-18 08:00AM  Todays Research Reports on Stocks to Watch: Loxo Oncology and Boston Scientific ACCESSWIRE -7.63%
Apr-04-18 06:45AM  Loxo Oncology Announces Acceptance of LOXO-292 Oral Presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting GlobeNewswire +10.09%
Apr-03-18 07:22AM  High-flying biotech Loxo tempers bullish view for cancer drug Reuters
07:00AM  FOCUS-High-flying biotech Loxo tempers bullish view for cancer drug Reuters
Mar-28-18 07:10AM  Blog Exposure - Loxo Oncology Completed Rolling Submission of NDA to the FDA for Larotrectinib for TRK Fusion Cancer Treatment ACCESSWIRE
Mar-26-18 06:45AM  Loxo Oncology Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Larotrectinib for the Treatment of TRK Fusion Cancer GlobeNewswire +5.47%
06:45AM  Bayer Announces Completion of Rolling Submission of New Drug Application in the U.S. for Larotrectinib for the Treatment of TRK Fusion Cancer PR Newswire
Mar-21-18 11:59AM  Turning Neutral: Morgan Stanley Downgrades Sarepta, Loxo Oncology, Global Blood Therapeutics Benzinga
08:30AM  Todays Research Reports on Trending Tickers: AnaptysBio and Loxo Oncology ACCESSWIRE
Mar-13-18 08:15AM  Report: Developing Opportunities within Lululemon Athletica Inc., Loxo Oncology, MakeMyTrip, Sumitomo Mitsui Financial Group, Seagate Technology, and New York Mortgage Trust Future Expectations, Projections Moving into 2018 GlobeNewswire
Mar-06-18 06:45AM  Loxo Oncology to Present at the Cowen and Company 38th Annual Health Care Conference GlobeNewswire
Mar-01-18 10:21PM  Edited Transcript of LOXO earnings conference call or presentation 1-Mar-18 1:00pm GMT Thomson Reuters StreetEvents
07:53AM  Loxo reports 4Q loss Associated Press
06:45AM  Loxo Oncology Reports Fourth Quarter and Year-End 2017 Financial Results GlobeNewswire
06:15AM  Loxo Oncology Inc to Host Earnings Call ACCESSWIRE
Feb-28-18 06:35AM  Should You Buy Loxo Oncology (LOXO) Ahead of Earnings? Zacks
Feb-22-18 08:10AM  Todays Research Reports on Stocks to Watch: Halozyme Therapeutics and Loxo Oncology ACCESSWIRE
06:45AM  Loxo Oncology to Announce Fourth Quarter and Year-End 2017 Financial Results GlobeNewswire
Feb-21-18 05:00PM  Loxo Oncology Announces Publication of Larotrectinib Clinical Data in The New England Journal of Medicine GlobeNewswire
05:00PM  Bayer Announces Publication of Larotrectinib Data in The New England Journal of Medicine PR Newswire
Jan-25-18 09:02AM  Taking Stock of Arrowhead Pharmaceuticals Financial Performance Market Realist
07:32AM  What Led to Arrowhead Pharmaceuticals Revenue Surge in 2017? Market Realist
Jan-24-18 01:30PM  Arrowheads Candidates for Hepatitis B, Cardiovascular Diseases Market Realist
12:00PM  Taking a Closer Look at Arrowhead Pharmaceuticals TRIM Platform Market Realist
10:25AM  Analysts Recommendations for Arrowhead and Its Peers Market Realist
Jan-15-18 08:07AM  See what the IHS Markit Score report has to say about Loxo Oncology Inc. Markit
Jan-10-18 07:37AM  Inside Ignytas Financial Performance Market Realist
Jan-09-18 02:15PM  A Close Look at Ignytas Licensing Agreement Market Realist
Loxo Oncology, Inc., a biopharmaceutical company, develops and sells medicines for patients with genetically defined cancers in the United States. Its lead product candidate comprises larotrectinib, an oral selective inhibitor of tropomyosin receptor kinase (TRK), which is in adult Phase 1 trial, a pediatric Phase 1/2 trial, and an adult/adolescent Phase 2 trial for the treatment of patients with tumor types, such as lung, head and neck, melanoma, colorectal, sarcoma, and breast cancer. The company's preclinical programs include LOXO-195, a drug candidate in preclinical development to address predicted acquired resistance mechanisms; RET inhibitor that optimizes potency for rearranged during transfection (RET) fusion proteins, mutations, and anticipated mechanisms of acquired resistance; and FGFR inhibitor that enables potently inhibiting FGFR isoforms comprising four isoforms with tyrosine kinase domains. It has a drug discovery collaboration agreement with Array BioPharma, Inc. to obtain various rights to TRK inhibitor program and oncology targets; strategic partnership with Illumina, Inc. to develop and commercialize a multi-gene panel for broad tumor profiling; and research collaboration agreement with Veracyte, Inc. to develop medicines for patients with genetically defined cancers. Loxo Oncology, Inc. was founded in 2013 and is headquartered in Stamford, Connecticut.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Van Naarden JacobChief Business OfficerSep 13Option Exercise3.654,50016,41618,200Sep 14 06:14 PM
Bilenker Joshua H.President & CEOSep 13Option Exercise1.8110,00018,067145,407Sep 14 06:17 PM
Burstein JenniferSenior VP of FinanceSep 13Option Exercise11.351,25014,1881,250Sep 14 06:19 PM
Van Naarden JacobChief Business OfficerSep 13Sale165.984,500746,90313,700Sep 14 06:14 PM
Bilenker Joshua H.President & CEOSep 13Sale165.9810,0001,659,805135,407Sep 14 06:17 PM
Burstein JenniferSenior VP of FinanceSep 13Sale166.021,250207,5230Sep 14 06:19 PM
Van Naarden JacobChief Business OfficerSep 12Option Exercise3.655,50020,06419,200Sep 14 06:14 PM
Bilenker Joshua H.President & CEOSep 12Option Exercise1.1810,00011,840145,407Sep 14 06:17 PM
Burstein JenniferSenior VP of FinanceSep 12Option Exercise11.351,25014,1881,250Sep 14 06:19 PM
Van Naarden JacobChief Business OfficerSep 12Sale166.605,500916,27613,700Sep 14 06:14 PM
Bilenker Joshua H.President & CEOSep 12Sale166.4210,0001,664,159135,407Sep 14 06:17 PM
Burstein JenniferSenior VP of FinanceSep 12Sale167.891,250209,8690Sep 14 06:19 PM
Bilenker Joshua H.President & CEOAug 14Option Exercise1.1810,00011,840145,407Aug 15 05:23 PM
Burstein JenniferSenior VP of FinanceAug 14Option Exercise11.351,25014,1881,250Aug 15 05:25 PM
Van Naarden JacobChief Business OfficerAug 14Option Exercise3.654,50016,41618,200Aug 15 05:27 PM
Bilenker Joshua H.President & CEOAug 14Sale159.9110,0001,599,089135,407Aug 15 05:23 PM
Burstein JenniferSenior VP of FinanceAug 14Sale160.221,250200,2790Aug 15 05:25 PM
Van Naarden JacobChief Business OfficerAug 14Sale159.924,500719,64213,700Aug 15 05:27 PM
Bilenker Joshua H.President & CEOAug 13Option Exercise1.1810,00011,840145,407Aug 15 05:23 PM
Burstein JenniferSenior VP of FinanceAug 13Option Exercise11.351,25014,1881,250Aug 15 05:25 PM
Van Naarden JacobChief Business OfficerAug 13Option Exercise3.655,50020,06419,200Aug 15 05:27 PM
Bilenker Joshua H.President & CEOAug 13Sale158.9110,0001,589,092135,407Aug 15 05:23 PM
Burstein JenniferSenior VP of FinanceAug 13Sale158.261,250197,8270Aug 15 05:25 PM
Van Naarden JacobChief Business OfficerAug 13Sale158.875,500873,80413,700Aug 15 05:27 PM
Bilenker Joshua H.President & CEOJul 10Option Exercise1.187,5008,880142,907Jul 11 05:01 PM
Van Naarden JacobChief Business OfficerJul 10Option Exercise3.651,5415,62215,241Jul 11 05:03 PM
Bilenker Joshua H.President & CEOJul 10Sale179.727,5001,347,923135,407Jul 11 05:01 PM
Van Naarden JacobChief Business OfficerJul 10Sale179.691,541276,90713,700Jul 11 05:03 PM
AISLING CAPITAL III LP10% OwnerJul 10Sale179.431,400,000251,202,0002,038,920Jul 12 04:45 PM
Bilenker Joshua H.President & CEOJul 09Option Exercise1.187,5008,880142,907Jul 11 05:01 PM
Van Naarden JacobChief Business OfficerJul 09Option Exercise3.651,5415,62215,241Jul 11 05:03 PM
Burstein JenniferSenior VP of FinanceJul 09Option Exercise11.351,50017,0251,500Jul 11 05:04 PM
Bilenker Joshua H.President & CEOJul 09Sale187.237,5001,404,241135,407Jul 11 05:01 PM
Van Naarden JacobChief Business OfficerJul 09Sale187.301,541288,63113,700Jul 11 05:03 PM
Burstein JenniferSenior VP of FinanceJul 09Sale187.251,500280,8700Jul 11 05:04 PM
Bilenker Joshua H.President & CEOJun 20Option Exercise1.1835,50042,032163,207Jun 21 05:02 PM
Van Naarden JacobChief Business OfficerJun 20Option Exercise3.6513,54149,39813,541Jun 21 05:03 PM
Bilenker Joshua H.President & CEOJun 20Sale179.257,5001,344,405155,707Jun 21 05:02 PM
Bilenker Joshua H.President & CEOJun 20Sale179.3321,0003,765,8328,000Jun 21 05:02 PM
Van Naarden JacobChief Business OfficerJun 20Sale179.341,541276,37012,000Jun 21 05:03 PM
Bilenker Joshua H.President & CEOJun 19Option Exercise1.187,5008,880135,207Jun 21 05:02 PM
Van Naarden JacobChief Business OfficerJun 19Option Exercise3.651,5415,6221,541Jun 21 05:03 PM
Burstein JenniferSenior VP of FinanceJun 19Option Exercise11.351,70019,2951,700Jun 21 05:04 PM
Bilenker Joshua H.President & CEOJun 19Sale177.047,5001,327,766127,707Jun 21 05:02 PM
Bilenker Joshua H.President & CEOJun 19Sale178.2521,0003,743,35329,000Jun 21 05:02 PM
Van Naarden JacobChief Business OfficerJun 19Sale176.941,541272,6660Jun 21 05:03 PM
Burstein JenniferSenior VP of FinanceJun 19Sale176.991,700300,8880Jun 21 05:04 PM
Kunkel Lori AnneDirectorJun 15Sale176.866,8401,209,6890Jun 18 05:00 PM
Kunkel Lori AnneDirectorJun 14Option Exercise6.5432,392211,70839,232Jun 18 05:00 PM
Kunkel Lori AnneDirectorJun 14Sale180.4632,3925,845,5646,840Jun 18 05:00 PM
Fuhrman AlanDirectorJun 08Option Exercise11.352,62529,7942,625Jun 11 06:01 PM
MAYLEBEN TIMOTHY MDirectorJun 08Option Exercise21.7510,000217,55010,000Jun 11 06:02 PM
Fuhrman AlanDirectorJun 08Sale178.072,625467,4370Jun 11 06:01 PM
MAYLEBEN TIMOTHY MDirectorJun 08Sale179.5510,0001,795,4690Jun 11 06:02 PM
Flaherty Keith T.DirectorJun 07Option Exercise1.1850,00059,20059,732Jun 11 06:00 PM
Flaherty Keith T.DirectorJun 07Sale173.5450,0008,677,0279,732Jun 11 06:00 PM
Bilenker Joshua H.President & CEOMay 15Option Exercise1.187,5008,880190,207May 16 04:44 PM
Van Naarden JacobChief Business OfficerMay 15Option Exercise3.651,5415,6221,541May 16 04:46 PM
Van Naarden JacobChief Business OfficerMay 15Sale137.291,541211,5660May 16 04:46 PM
Bilenker Joshua H.President & CEOMay 15Sale137.417,5001,030,575182,707May 16 04:44 PM
Bilenker Joshua H.President & CEOMay 14Option Exercise1.187,5008,880190,207May 16 04:44 PM
Van Naarden JacobChief Business OfficerMay 14Option Exercise3.651,5415,6221,541May 16 04:46 PM
Burstein JenniferSenior VP of FinanceMay 14Option Exercise11.351,70019,2951,700May 16 04:45 PM
Burstein JenniferSenior VP of FinanceMay 14Sale136.931,700232,7840May 16 04:45 PM
Van Naarden JacobChief Business OfficerMay 14Sale137.541,541211,9490May 16 04:46 PM
Bilenker Joshua H.President & CEOMay 14Sale135.617,5001,017,071182,707May 16 04:44 PM
Bilenker Joshua H.President & CEOApr 25Option Exercise1.187,5008,880190,207Apr 26 04:31 PM
Van Naarden JacobChief Business OfficerApr 25Option Exercise3.651,5415,6221,541Apr 26 04:32 PM
Van Naarden JacobChief Business OfficerApr 25Sale130.801,541201,5630Apr 26 04:32 PM
Bilenker Joshua H.President & CEOApr 25Sale130.867,500981,423182,707Apr 26 04:31 PM
Bilenker Joshua H.President & CEOApr 24Option Exercise1.187,5008,880190,207Apr 26 04:31 PM
Van Naarden JacobChief Business OfficerApr 24Option Exercise3.651,5415,6221,541Apr 26 04:32 PM
Burstein JenniferSenior VP of FinanceApr 24Option Exercise11.351,70019,2951,700Apr 26 04:33 PM
Burstein JenniferSenior VP of FinanceApr 24Sale131.651,700223,8050Apr 26 04:33 PM
Van Naarden JacobChief Business OfficerApr 24Sale131.671,541202,8980Apr 26 04:32 PM
Bilenker Joshua H.President & CEOApr 24Sale131.397,500985,430182,707Apr 26 04:31 PM
Kunkel Lori AnneDirectorApr 20Sale132.685,000663,3786,840Apr 24 04:30 PM
Bilenker Joshua H.President & CEOMar 14Option Exercise1.187,5008,880190,207Mar 15 05:00 PM
Van Naarden JacobChief Business OfficerMar 14Option Exercise3.651,5415,6221,541Mar 15 05:01 PM
Van Naarden JacobChief Business OfficerMar 14Sale131.461,541202,5800Mar 15 05:01 PM
Bilenker Joshua H.President & CEOMar 14Sale131.507,500986,215182,707Mar 15 05:00 PM
Bilenker Joshua H.President & CEOMar 13Option Exercise1.187,5008,880190,207Mar 15 05:00 PM
Van Naarden JacobChief Business OfficerMar 13Option Exercise3.651,5415,6221,541Mar 15 05:01 PM
Burstein JenniferSenior VP of FinanceMar 13Option Exercise11.351,70019,2951,700Mar 15 05:02 PM
Burstein JenniferSenior VP of FinanceMar 13Sale131.331,700223,2620Mar 15 05:02 PM
Van Naarden JacobChief Business OfficerMar 13Sale131.351,541202,4150Mar 15 05:01 PM
Bilenker Joshua H.President & CEOMar 13Sale131.587,500986,842182,707Mar 15 05:00 PM
Bilenker Joshua H.President & CEOFeb 13Option Exercise1.187,5008,880190,207Feb 14 05:36 PM
Van Naarden JacobChief Business OfficerFeb 13Option Exercise3.651,5415,6221,541Feb 14 05:35 PM
Van Naarden JacobChief Business OfficerFeb 13Sale99.241,541152,9340Feb 14 05:35 PM
Bilenker Joshua H.President & CEOFeb 13Sale99.757,500748,152182,707Feb 14 05:36 PM
Bilenker Joshua H.President & CEOFeb 12Option Exercise1.187,5008,880190,207Feb 14 05:36 PM
Van Naarden JacobChief Business OfficerFeb 12Option Exercise3.651,5415,6221,541Feb 14 05:35 PM
Burstein JenniferSenior VP of FinanceFeb 12Option Exercise11.351,70019,2951,700Feb 14 05:37 PM
Burstein JenniferSenior VP of FinanceFeb 12Sale93.241,700158,5040Feb 14 05:37 PM
Van Naarden JacobChief Business OfficerFeb 12Sale93.431,541143,9780Feb 14 05:35 PM
Bilenker Joshua H.President & CEOFeb 12Sale93.387,500700,377182,707Feb 14 05:36 PM
Naider Avi Z.DirectorJan 22Sale100.0015,0001,500,000126,118Jan 25 05:09 PM
Bilenker Joshua H.President & CEOJan 17Option Exercise1.187,5008,880190,207Jan 18 05:01 PM
Van Naarden JacobChief Business OfficerJan 17Option Exercise3.651,5415,6221,541Jan 18 05:02 PM